MannKind Corporation
http://www.mannkindcorp.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MannKind Corporation
Appetite For Korean Biotechs Turns Sour, Voronoi Withdraws IPO
Weak broader stock market sentiment, topped with negative biotech industry news, weighs on Korean bioventure IPOs in the first quarter, with unicorn Voronoi withdrawing its IPO plan. But VC financing in the sector remains steady.
The Race Is On. When Will Korea Have Its Own Approved Gene Therapy?
Scrip takes a look at the landscape of the South Korean gene and cell therapy sector, which is under the spotlight with the implementation of a new cutting-edge biologics law.
5 Dealmaking Trends To Watch In 2022
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
Keeping Track: Jardiance Approved Across Heart Failure Spectrum, But US FDA Turns Down Bardoxolone, Terlipressin
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
- Other Names / Subsidiaries
-
- QrumPharma, Inc.